This year, the American Society of Hematology (ASH) celebrated its 50th anniversary. The goal of ASH is to prevent and cure hematological diseases through the advancement and sponsorship of basic and clinical research. This year's ASH meeting addressed important research topics including hematologic malignancies, bone marrow transplantation, sickle cell diseases, hematopoietic stem cells, thrombosis, hemostasis, and vascular biology. This report will focus on 1) the discovery of novel anti-coagulant agents, 2) the role of cell-surface molecules in vascular diseases such as sickle cell disease and inflammation, 3) the role of endothelial cells, platelets, and leukocytes in cancer, and 4) the platelet
(http://www.hematology.org).
Keywords: vascular disease, thrombosis and hemostasis, inflammation, sickle cell disease, cancer I. Satellite Symposium: There were several Satellite Symposiums preceding the annual meeting. One such symposium, "New Perspectives and Strategies in Venous Thromboembolic Disease" illustrated the weaknesses of currently available anticoagulants, described molecular mechanisms of factor Xa and thrombin inhibitors and their merits, and showed data from clinical trials of novel anticoagulants under development for effective prevention of venous thromboembolism. This has been a popular topic for
ASH and other thrombosis conference including ISTH (International Society on Thrombosis and
Haemostasis). New results regarding novel inhibitors of factor Xa and thrombin were also discussed. Dr.
Charles T. Esmon (HHMI, Oklahoma Medical Research Foundation) explained the role of factor Xa and thrombin in the blood coagulation cascade. After vascular injury, tissue factor (a major initiator for blood coagulation) binds to factor VIIa. This complex activates factor X to factor Xa, thereby producing thrombin. Since factor Xa and thrombin are essential for fibrin formation, both molecules could be an attractive target for novel anti-coagulants. The major role of factor Xa is limited to thrombin generation, whereas thrombin regulates many responses including anticoagulation (through protein C activation and prostacyclin production), procoagulation (by feedback activation of coagulation factors), inflammation (by intravascular cell activation), and cellular proliferation (by PDGF and TGF production). Therefore,  he mentioned that factor Xa inhibitors would inhibit blood coagulation specifically. In contrast, thrombin inhibitors might result in unwanted effects. More importantly, factor Xa activates blood clotting over a wider concentration range than thrombin. These results suggest that factor Xa inhibitors may have increased potency with lesser bleeding effects than thrombin inhibitors and could be safer. In his talk, he explained the molecular mechanism of erythrocyte vaso-occlusion in SCD using multichannel fluorescence intravital microscopy with pharmacologic and genetic approaches. Sickle 5 erythocytes interact specifically with adherent neutrophils. Most adherent neutrophils crawl along the inflamed venules, and endothelial cell E-and P-selectins are key molecules in vaso-occlusion in SCD.
Recent work from his group (Hidalgo et al. Immunity 2007; 26:477-89) has demonstrated that E-selectinmediated signaling in adherent leukocytes plays a critical role in interaction of erythrocytes with adherent neutrophils. Further, they found that E-selectin ligand-1 mediates E-selectin-induced signaling and that alphaMbeta2 (Mac-1) mediates erythrocyte capture on adherent leukocytes. In sum, leukocytes
adhere to E-selectin on the inflamed endothelial cells through leukocyte E-selectin ligand-1, which activates alphaMbeta2 regionally at the leading edge and allows erythrocyte adhesion to adherent leukocytes. These results give novel insight into how vaso-occlusion occurs in SCD.
Dr. Andy Weyrich (University of Utah) has been studying the machinery to produce new proteins in platelets. It was believed that platelets lack mRNA and translational factors and do not synthesize proteins. However, his work has demonstrated that platelets possess translational machinery consisting of ribosomes, mRNA, and translational factors and do synthesize proteins. In my opinion, these findings are still controversial because it is extremely hard to obtain pure platelets from blood without contamination from leukocytes. Therefore, some people still suspect that his observation is derived from contamination. This year, he showed that circulating platelets are divided into new platelets. Platelets are differentiated from megakaryocytes through proplatelets. Real-time microscopic images showed that platelets form cell bodies and generate more platelets in a platelet activation-independent manner. He also found that platelets cultured in serum-free media increase the mass and number. However, someone asked whether cultured platelets behave like circulating platelets in blood.
In blood, her group found that biologically active CD40L is released from platelets of SCD patients, thereby increasing the level of soluble CD40L to 30-fold in patients' blood. Treatment with integrilin (a specific antagonist for platelet alphaIIbbeta3 integrin, Millennium Pharmaceuticals) prevented release of soluble CD40L from patients' platelets, suggesting that platelet alphaIIbbeta3 integrin plays an important role in CD40L release. She also focused on how multicellular aggregates form in the blood of SCD patients. She explained that platelets interact with monocytes through the interaction of P-selectin with PSGL-1. Moreover, plasma fibronectin links monocytes to red blood cells through recognition of alpha4beta1 integrin expressed on either cell. Therefore, she concluded that soluble factors such as
